AstraZeneca builds Asian R&D blocks with LegoChem antibiotics alliance
This article was originally published in Scrip
Executive Summary
In its second R&D alliance with an Asian partner this week, AstraZeneca has entered into an option and license agreement with the South Korean firm LegoChem Biosciences for the early development of novel antibacterials.